drugset / Trial / NCT02182349

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

NCT02182349

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to determine the pharmacokinetics (PK) of BI 201335 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of \[14C\]-BI 201335 at steady state.

Timeline

Start
2009-06
Primary completion
2009-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule 240 mg Oral

Indications

No indication recorded.